902 Shares in Insulet Co. (NASDAQ:PODD) Acquired by Sagespring Wealth Partners LLC

Sagespring Wealth Partners LLC purchased a new stake in Insulet Co. (NASDAQ:PODD) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 902 shares of the medical instruments supplier’s stock, valued at approximately $235,000.

Other large investors have also recently bought and sold shares of the company. Horizon Investments LLC boosted its stake in shares of Insulet by 3.1% in the 4th quarter. Horizon Investments LLC now owns 1,387 shares of the medical instruments supplier’s stock valued at $362,000 after purchasing an additional 42 shares in the last quarter. Nisa Investment Advisors LLC boosted its position in Insulet by 1.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 4,388 shares of the medical instruments supplier’s stock valued at $1,146,000 after buying an additional 43 shares in the last quarter. Graypoint LLC grew its stake in Insulet by 5.3% during the fourth quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after buying an additional 47 shares during the last quarter. Wilmington Savings Fund Society FSB grew its stake in Insulet by 9.6% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 538 shares of the medical instruments supplier’s stock worth $140,000 after buying an additional 47 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its holdings in shares of Insulet by 2.3% during the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 2,113 shares of the medical instruments supplier’s stock worth $552,000 after buying an additional 48 shares in the last quarter.

Insulet Stock Performance

PODD stock opened at $250.73 on Thursday. The company has a quick ratio of 2.80, a current ratio of 3.68 and a debt-to-equity ratio of 1.21. Insulet Co. has a twelve month low of $160.19 and a twelve month high of $289.46. The business’s fifty day moving average is $264.81 and its 200-day moving average is $260.62. The company has a market cap of $17.61 billion, a P/E ratio of 43.30, a price-to-earnings-growth ratio of 3.62 and a beta of 1.30.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. The business had revenue of $597.50 million for the quarter, compared to the consensus estimate of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Equities research analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on PODD. Citigroup increased their price target on Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a research report on Friday, February 21st. TD Cowen increased their target price on Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Canaccord Genuity Group raised their target price on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Raymond James reiterated an “outperform” rating and set a $328.00 price target (up previously from $294.00) on shares of Insulet in a research report on Friday, February 21st. Finally, Royal Bank of Canada initiated coverage on shares of Insulet in a research report on Thursday, March 6th. They issued an “outperform” rating and a $340.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $292.06.

Insider Transactions at Insulet

In related news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the sale, the executive vice president now owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Wayne A.I. Frederick sold 1,825 shares of the business’s stock in a transaction dated Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total value of $501,875.00. Following the completion of the transaction, the director now directly owns 3,231 shares of the company’s stock, valued at approximately $888,525. The trade was a 36.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.47% of the company’s stock.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.